Stimulant effects of adenosine antagonists on operant behavior: differential actions of selective A2A and A1 antagonists

被引:36
|
作者
Randall, Patrick A. [1 ]
Nunes, Eric J. [1 ]
Janniere, Simone L. [1 ]
Stopper, Colin M. [1 ]
Farrar, Andrew M. [1 ]
Sager, Thomas N. [2 ]
Baqi, Younis [3 ]
Hockemeyer, Joerg [3 ]
Mueller, Christa E. [3 ]
Salamone, John D. [1 ]
机构
[1] Univ Connecticut, Dept Psychol, Storrs, CT 06269 USA
[2] H Lundbeck & Co AS, Pharmacol Target Res, DK-2500 Copenhagen, Denmark
[3] Univ Bonn, Inst Pharmazeut, Pharma Zentrum Bonn, D-5300 Bonn, Germany
关键词
Activation; Anergia; Psychomotor slowing; Depression; Dopamine; Parkinsonism; SCHEDULE-CONTROLLED BEHAVIOR; D-AMPHETAMINE; RECEPTOR ANTAGONISTS; NUCLEUS-ACCUMBENS; SYMPATHOMIMETIC AMINES; LOCOMOTOR SUPPRESSION; DECISION-MAKING; MSX-3; REVERSES; CAFFEINE; DOPAMINE;
D O I
10.1007/s00213-011-2198-3
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Adenosine A(2A) antagonists can reverse many of the behavioral effects of dopamine antagonists, including actions on instrumental behavior. However, little is known about the effects of selective adenosine antagonists on operant behavior when these drugs are administered alone. The present studies were undertaken to investigate the potential for rate-dependent stimulant effects of both selective and nonselective adenosine antagonists. Six drugs were tested: two nonselective adenosine antagonists (caffeine and theophylline), two adenosine A(1) antagonists (DPCPX and CPT), and two adenosine A(2A) antagonists (istradefylline (KW6002) and MSX-3). Two schedules of reinforcement were employed; a fixed interval 240-s (FI-240 sec) schedule was used to generate low baseline rates of responding and a fixed ratio 20 (FR20) schedule generated high rates. Caffeine and theophylline produced rate-dependent effects on lever pressing, increasing responding on the FI-240 sec schedule but decreasing responding on the FR20 schedule. The A(2A) antagonists MSX-3 and istradefylline increased FI-240 sec lever pressing but did not suppress FR20 lever pressing in the dose range tested. In fact, there was a tendency for istradefylline to increase FR20 responding at a moderate dose. A(1) antagonists failed to increase lever pressing rate, but DPCPX decreased FR20 responding at higher doses. These results suggest that adenosine A(2A) antagonists enhance operant response rates, but A(1) antagonists do not. The involvement of adenosine A(2A) receptors in regulating aspects of instrumental response output and behavioral activation may have implications for the treatment of effort-related psychiatric dysfunctions, such as psychomotor slowing and anergia in depression.
引用
收藏
页码:173 / 186
页数:14
相关论文
共 50 条
  • [31] A2A Adenosine Receptor Antagonists: Are Triazolotriazine and Purine Scaffolds Interchangeable?
    Spinaci, Andrea
    Lambertucci, Catia
    Buccioni, Michela
    Dal Ben, Diego
    Graiff, Claudia
    Barbalace, Maria Cristina
    Hrelia, Silvana
    Angeloni, Cristina
    Tayebati, Seyed Khosrow
    Ubaldi, Massimo
    Masi, Alessio
    Klotz, Karl-Norbert
    Volpini, Rosaria
    Marucci, Gabriella
    MOLECULES, 2022, 27 (08):
  • [32] A2A Adenosine Receptor Antagonists and Their Efficacy in Rat Models of Parkinson's Disease
    Spinaci, Andrea
    Buccioni, Michela
    Dal Ben, Diego
    Francucci, Beatrice
    Klotz, Karl-Norbert
    Marucci, Gabriella
    Simola, Nicola
    Morelli, Micaela
    Pinna, Annalisa
    Volpini, Rosaria
    Lambertucci, Catia
    CELLS, 2025, 14 (05)
  • [33] Pharmacological interactions between adenosine A2A receptor antagonists and different neurotransmitter systems
    Pinna, Annalisa
    Serra, Marcello
    Marongiu, Jacopo
    Morelli, Micaela
    PARKINSONISM & RELATED DISORDERS, 2020, 80 : S37 - S44
  • [34] Can adenosine A2A receptor antagonists modify motor behavior and dyskinesia in experimental models of Parkinson's disease?
    Kanda, Tomoyuki
    Jenner, Peter
    PARKINSONISM & RELATED DISORDERS, 2020, 80 : S21 - S27
  • [35] Adenosine A2A receptor antagonists: Potential therapeutic and neuroprotective effects in parkinson’s disease
    M. Morelli
    J. Wardas
    Neurotoxicity Research, 2001, 3 : 545 - 556
  • [36] Discovery of 1,3-diethyl-7-methyl-8-(phenoxymethyl)-xanthine derivatives as novel adenosine A1 and A2A receptor antagonists
    Harmse, Rozanne
    van der Walt, Mietha M.
    Petzer, Jacobus P.
    Terre'Blanche, Gisella
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2016, 26 (24) : 5951 - 5955
  • [37] Identification and optimization of substituted 5-aminopyrazoles as potent and selective adenosine A1 receptor antagonists
    Griebenow, Nils
    Baerfacker, Lars
    Meier, Heinrich
    Schneider, Dirk
    Teusch, Nicole
    Lustig, Klemens
    Kast, Raimund
    Kolkhof, Peter
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (19) : 5891 - 5894
  • [38] Adenosine A2A Receptor Antagonists as a Treatment Option for Parkinson's Disease?
    Jost, Wolfgang H.
    Toenges, Lars
    FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE, 2022, 90 (12) : 565 - 570
  • [39] Novel Quinazoline Derivatives as Highly Effective A2A Adenosine Receptor Antagonists
    Laversin, Amelie
    Dufossez, Robin
    Bolteau, Raphael
    Duroux, Romain
    Ravez, Severine
    Hernandez-Tapia, Sergio
    Fossart, Martin
    Coevoet, Mathilde
    Liberelle, Maxime
    Yous, Said
    Lebegue, Nicolas
    Melnyk, Patricia
    MOLECULES, 2024, 29 (16):
  • [40] A2A Adenosine Receptor Antagonists as Therapeutic Candidates: Are They Still an Interesting Challenge?
    Cacciari, Barbara
    Spalluto, Giampiero
    Federico, Stephanie
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2018, 18 (14) : 1168 - 1174